John T. Augelli

I'll research this attorney's background before drafting.

Let me verify the firm move and the tracked Flexiworld cases.

Let me verify the AngioDynamics outcome and any named PTAB appearances.

John T. Augelli — patent litigation practice summary

Focus areas. Augelli is a New York–based IP litigator with an electrical-and-computer-engineering background, and his docket skews toward electronics and networking-adjacent subject matter. In the tracked matters he defended Brother in the Flexiworld Technologies campaign, which asserted patents on driverless/cloud and wireless (Wi-Fi, AirPrint, Mopria, Google Cloud Print) printing. His firm bio describes patent work spanning enterprise content-management software (Hyland/Alfresco), endodontic tools (Dentsply Sirona), implantable vascular access devices (AngioDynamics), semiconductor/telecom matters, ITC actions, and a pharmaceutical arbitration — so his practice is broad rather than pharma- or mechanical-specific, with a notable concentration in Section 101/eligibility and printed-matter disputes.

Side preference. He is a defense-side litigator. The authoritative case list shows 3 defendant-side appearances and 0 plaintiff-side appearances, all in NPE/PAE suits (Flexiworld is a licensing-oriented, "failed startup"–category asserter). His published matter list is consistent: he defends operating companies — Brother, AngioDynamics, Hyland, Dentsply Sirona, Anheuser-Busch InBev, a smart-ring manufacturer — rather than asserting patents for patent owners.

Firm context. The tracked appearances list him at Cadwalader, Wickersham & Taft, where he was an associate and appeared on the AngioDynamics trial team (firm press release, June 2023) and on the team credited with the resulting Federal Circuit win. Firm bios and the New York attorney registration indicate he has since moved to Orrick, Herrington & Sutcliffe in New York as a senior associate; his Orrick profile describes the same matters (Brother, AngioDynamics, Hyland) as his experience. Note the caveat that the case list reflects his Cadwalader tenure while current-firm information comes from the Orrick profile and bar records.

Notable matters. (1) C.R. Bard, Inc. v. AngioDynamics, Inc. — he was on the Cadwalader team that obtained JMOL of no infringement, no willfulness, and invalidity on Bard's power-injectable vascular access port patents after a trial in which Bard sought over $100 million; the Federal Circuit affirmed the invalidation in a nonprecedential decision (No. 23-2056, Dec. 15, 2025). This was the second appeal in a 12-year dispute, and the parties' April 2024 settlement included a $3 million contingent payment to Bard that was avoided by the affirmance. (2) Flexiworld Technologies, Inc. v. Brother Industries (U.S.A.), Inc. and related W.D. Tenn. actions — Brother moved to dismiss numerous direct, joint, and contributory infringement claims; the four coordinated cases were dismissed with prejudice by stipulation in March 2023. (3) Hyland/Alfresco — transfer of three W.D. Tex. cases to C.D. Cal. over Judge Albright's initial denial, with two asserted patents recommended § 101-ineligible. (4) A 5-day arbitration win for a small pharmaceutical company.

PTAB/IPR. His bios claim PTAB experience, including a covered business method review for Quantile in which all claims were found § 101-ineligible and PTAB work for Anheuser-Busch InBev, and ITC experience. I found no public record of him as a named lead or backup counsel on IPR/PGR petitions, so he appears to be a district-court-first litigator with team-level PTAB involvement rather than a high-volume IPR practitioner — a point worth verifying before relying on it.

Bar and education. Admitted in New York (2019), the U.S. Court of Appeals for the Federal Circuit, and the S.D.N.Y.; J.D., Brooklyn Law School (2018, cum laude; Brooklyn Law Review, Moot Court Honor Society); B.S. in Electrical and Computer Engineering, Lafayette College; previously a product development engineer at Amphenol. Named a Super Lawyers New York Rising Star for Intellectual Property (2023–2025).